(Total Views: 374)
Posted On: 09/07/2019 3:51:05 AM
Post# of 145915
Maybe. Though, maybe slowing down leronlimab’s approval looks good on a resume for BP. Just crazy.
Oh by the way, here is Maraviroc in MDR2, looks like at 24 weeks, VL<50 was around 45%. So leronlimab 325mg is better than maraviroc’s best, almost by double, same with IZ. Yet we still need better.
Also 17 patients died during this study. Did they really need a placebo group? Seems unethical.
https://www.nejm.org/doi/full/10.1056/nejmoa0803152
Oh by the way, here is Maraviroc in MDR2, looks like at 24 weeks, VL<50 was around 45%. So leronlimab 325mg is better than maraviroc’s best, almost by double, same with IZ. Yet we still need better.
Also 17 patients died during this study. Did they really need a placebo group? Seems unethical.
https://www.nejm.org/doi/full/10.1056/nejmoa0803152
![778828294_F2D6ADC7-CDD0-43C9-975B-C21726E4A391.jpeg](http://investorshangout.com/images/MYImages/778828294_F2D6ADC7-CDD0-43C9-975B-C21726E4A391.jpeg)
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)